Evidence map›Paper›PMID 30372677›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study.

Julian W Sacre, Dianna J Magliano, Paul Z Zimmet, Kevan R Polkinghorne, Steven J Chadban, Kaarin J Anstey, Jonathan E Shaw

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Insights into Cognitive Brain Health in Chronic Kidney Disease.Gerontology & geriatrics : research · 2022
    Article
  11. Review
  12. Article
  13. Diabetes, Albuminuria and the Kidney-Brain Axis.Journal of clinical medicine · 2021
    Review
  14. Article
  15. Mechanisms of cognitive dysfunction in CKD.Nature reviews. Nephrology · 2020
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Julian W SacreBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Dianna J MaglianoBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Paul Z ZimmetDepartment of Diabetes, Monash University, Melbourne, VIC, Australia.
Kevan R PolkinghorneDepartment of Nephrology, Monash Medical Centre, Monash Health, Melbourne, VIC, Australia.
Steven J ChadbanSydney Medical School, University of Sydney, NSW, Australia.
Kaarin J AnsteySchool of Psychology, University of New South Wales, Sydney, NSW, Australia.
Jonathan E ShawBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Baker Heart and Diabetes Institute · AUMonash Medical Centre · AUMonash University · AUThe Royal Melbourne Hospital · AUThe University of Sydney · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of chronic kidney disease (CKD) as a risk factor for cognitive impairment independent of their shared antecedents remains controversial.

objectiveTo determine whether kidney damage (indicated by albuminuria) or kidney dysfunction (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) predict future (12-year) cognitive function independently of their shared risk factors.

methodsWe studied 4,128 individuals from the 1999/00 population-based Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study who returned in 2011/12 for follow-up cognitive function testing. Albuminuria was defined by urinary albumin:creatinine≥3.5 (women) or≥2.5 mg/mmol (men). Kidney dysfunction was indicated by eGFR <60 ml/min/1.73 m2. Cognitive function domains assessed included memory (California Verbal Learning Test [CVLT]) and processing speed (Symbol Digit Modalities Test [SDMT]).

resultsBaseline albuminuria and kidney dysfunction were identified in 142 (3.4%) and 39 (0.9%) individuals, respectively, with minimal overlap (n = 7). Those with albuminuria demonstrated concurrently reduced 12-year SDMT (p = 0.084) and CVLT scores (p = 0.005) following adjustment for age, sex, and education. However, only CVLT performance remained worse (p = 0.027) following additional adjustment for myocardial infarction, stroke, and related risk factors (hypertension, diabetes, dyslipidemia, smoking, BMI, physical activity, and alcohol intake). Indeed, these collective covariates were responsible for 47% of the effect of albuminuria on SDMT, but only 21% of its effect on CVLT. Kidney dysfunction was not associated with either SDMT or CVLT performance (p > 0.10).

conclusionsAlbuminuria predicted worse memory function at 12 years follow-up, whereas its effect on processing speed was driven largely by differences in cardiovascular risk. Kidney dysfunction based on eGFR predicted neither cognitive domain.

Indexed as

AdultAgedAlbuminuriaBiomarkersCognitionCognitive DysfunctionFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidneyMaleMemoryMiddle AgedNeuropsychological TestsReaction TimeBiomarkersCardiovascular diseasescognition disorderscognitive declinecognitive impairmentcohort studieskidney diseases

Identifiers

PMID30372677
PMCPMC6700620
OpenAlexW2898553164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.